FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBio-Techne Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TECH
Bio-Techne Corporation Stock AnalysisComprehensive stock analysis for Bio-Techne Corporation (TECH) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTECH
TECH
Bio-Techne Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TECH
  1. Home
  2. Stocks
  3. Bio-Techne Corporation

Bio-Techne Corporation

🇺🇸TECH•NASDAQ

Bio-Techne Corporation

🇺🇸TECH•NASDAQ
Market cap
$11.43B
Sentiment

Your view on TECH

Mkt Cap
$11.43B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Bio-Techne Corporation

Industry
Biotechnology
Sector
Healthcare
CEO
Kim Kelderman
Headquarters
614 McKinley Place N.E., Minneapolis, MN, US
Industry
Biotechnology
Sector
Healthcare
CEO
Kim Kelderman
Headquarters
614 McKinley Place N.E., Minneapolis, MN, US
Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics.

The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.

The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.

It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.

Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Bio-Techne Corporation from FRC's valuation model, read against the market price. TECH last traded at $72.79, 66.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Bio-Techne Corporation. Starting points for Bio-Techne Corporation: P/E 66.2, EPS $1.10, beta 1.27 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Bio-Techne Corporation. Bio-Techne Corporation paid $0.40 per share over the last year — a 0.5% yield at the current $72.79 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Bio-Techne Corporation. Trailing twelve-month EPS for Bio-Techne Corporation stands at $1.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$67.18

average of 11 firms, last 12 months

 

$67.18

Low $50.00

Median $73.00

High $79.00

 

Analyst Ratings

Hold12 firms, last 12 months
  • Strong Buy0
  • Buy2
  • Hold10
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Jun 2027Next YearFY Jun 2028
Avg. estimate$0.47$0.55$2.05$2.36
Low estimate$0.45$0.53$1.86$2.20
High estimate$0.49$0.57$2.20$2.49
No. of analysts4455
Year-ago EPS$0.46$0.53$1.16—
Growth+2.2%+3.3%+77.0%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Jun 2027Next YearFY Jun 2028
Avg. estimate$308.75M$327.10M$1.27B$1.40B
Low estimate$305.21M$324.01M$1.25B$1.39B
High estimate$312.27M$328.76M$1.29B$1.43B
No. of analysts5597
Year-ago revenue$295.88M$311.42M$1.22B—
Growth+4.3%+5.0%+4.7%—
Recent analyst actions15 rating and price-target changes, latest Aug 13, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Bio-Techne Corporation. Bio-Techne Corporation has reported as a listed company since 1989. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold TECH20 companies · 8 funds
Compare TECH with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • AAgilent Technologies, Inc.Medical - Diagnostics & Research$48.8B
  • ALMRAlamar Biosciences, Inc.Biotechnology$2.1B
  • BIOBio-Rad Laboratories, Inc.Medical - Devices$9.7B
  • BRKRBruker CorporationMedical - Devices$9.3B
  • DHRDanaher CorporationMedical - Diagnostics & Research$161.9B
  • QGENQiagen N.V.Medical - Diagnostics & Research$10.3B
  • RVTYRevvity, Inc.Medical - Diagnostics & Research$16.6B
  • SEERSeer, Inc.Biotechnology$83M

More Biotechnology companies

  • CDTTWCDT Equity Inc.NASDAQ$5,704
  • CDXICardax, Inc.OTC$80
  • CDXSCodexis, Inc.NASDAQ$116M
  • CELCCelcuity Inc.NASDAQ$3.0B
  • CELUCelularity Inc.NASDAQ$20M
  • CELZCreative Medical Technology Holdings, Inc.NASDAQ$4M
  • CEROCERo Therapeutics Holdings, Inc.OTC$45,803
  • CEROWCERo Therapeutics Holdings, Inc.OTC
  • CFRXQContraFect CorporationOTC$107
  • CGEMCullinan Therapeutics, Inc.NASDAQ$617M
  • CGENCompugen Ltd.NASDAQ$193M
  • CGONCG Oncology, Inc. Common stockNASDAQ$7.6B

ETFs holding Bio-Techne Corporation

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.02%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.02%
  • VBVanguard Small-Cap ETF$76.9B in assets0.14%
  • RSPInvesco S&P 500 Equal Weight ETF$101.8B in assets0.20%
  • GNOMGlobal X - Genomics & Biotechnology ETF$108M in assets4.55%
  • MNANYLI Merger Arbitrage ETF$263M in assets3.46%
  • FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.33%
  • BBHVanEck Biotech ETF$536M in assets1.15%

Largest holders first, then the funds most concentrated in TECH.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Bio-Techne Corporation, and how their positions are changing. At a $11.43B market value, institutional positions materially move Bio-Techne Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Bio-Techne Corporation executives and directors. Shares of Bio-Techne Corporation have traded between $46.01 and $79.28 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Bio-Techne Corporation. Bio-Techne Corporation is a $11.43B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Bio-Techne Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Bio-Techne Corporation. Coverage tracks Bio-Techne Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Bio-Techne Corporation.

TECH Analysis
Fair
Past4
Growth2
Health4
Profit2
Value1

News

Latest Market News